Literature DB >> 7063048

Actions of co-dergocrine mesylate and its components at vascular smooth muscle.

E Müller-Schweinitzer.   

Abstract

The mechanisms by which co-dergocrine mesylate (CODE) and its components modify vascular tone was investigated in vitro. Changes in tension were monitored isometrically on spiral strips of canine basilar arteries and femoral veins suspended in 10 ml organ baths and on spiral strips of canine saphenous veins superfused between two platinum electrodes for electric stimulation (150 mA, 0.1 ms, 2 Hz) and measurement of tritium overflow. Cumulative concentration-response curves were established for 5-hydroxytryptamine (5-HT), noradrenaline (NA), dihydroergocornine (DHCO), dihydroergocristine (DHEC), dihydro-alpha-ergokryptine (DH alpha E), dihydro-beta-ergokryptine (DH beta E) and CODE. CODE and its single components were about equally potent in antagonizing responses to 5-HT on basilar arteries. On femoral veins DHEC antagonized responses to NA noncompetitively whereas the other components caused competitive antagonism against NA. Compared to CODE, DH alpha E and DH beta E, the alpha-blocking potency of both DHCO and DHEC was about 10 times weaker. All 5 ergot compounds were about equally potent in antagonizing contractile responses to electric stimulation of saphenous veins whereas the stimulation-induced overflow of labeled NA was inhibited in the following order of potency: CODE greater than or equal to DHCO greater than DH alpha E greater than DH beta E greater than DHEC. The 5 ergot compounds stimulated arterial and venous smooth muscle at slightly higher concentrations than necessary for antagonism of 5-HT or NA. Evidence is presented that the mechanism of the stimulant action on arteries differs from that on veins. It is suggested that the diversity of actions of CODE is the base for its therapeutic effectiveness in patients suffering from regional vascular disorders.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7063048     DOI: 10.1007/bf00500484

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  23 in total

1.  The effects of certain dihydrogenated alkaloids of ergot in hypertensive patients.

Authors:  E D FREIS; J R STANTON; R W WILKINS
Journal:  Am J Med Sci       Date:  1948-08       Impact factor: 2.378

2.  Observations on the action of the hydrogenated alkaloids of the ergotoxine group on the circulation in man.

Authors:  H BARCROFT; H KONZETT; H J C SWAN
Journal:  J Physiol       Date:  1951-02       Impact factor: 5.182

3.  [Effect of hydrated ergot alkaloids on arterial and venous pressure].

Authors:  D HAMMERSCHMIDT; F ODENTHAL
Journal:  Z Kreislaufforsch       Date:  1950-03

4.  Responsiveness of isolated canine cerebral and peripheral arteries to ergotamine.

Authors:  E Müller-Schweinitzer
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1976       Impact factor: 3.000

5.  Studies of the effect of natural and synthetic polypeptide type ergot compounds on a peripheral vascular bed.

Authors:  W H Aellig; B Berde
Journal:  Br J Pharmacol       Date:  1969-07       Impact factor: 8.739

6.  The specific activity of retained and released norepinephrine in dog saphenous vein prelabeled with radiolabeled norepinephrine.

Authors:  D K Rorie; S M Muldoon; G M Tyce
Journal:  Life Sci       Date:  1980-03-03       Impact factor: 5.037

7.  Vasodilators in senile dementia.

Authors:  W P Maclay
Journal:  Br Med J       Date:  1979-10-06

8.  Enhanced prostaglandin synthesis contributes to the venoconstrictor activity of ergotamine.

Authors:  E Müller-Schweinitzer; J Brundell
Journal:  Blood Vessels       Date:  1975

9.  Mechanism of the inhibitory action of indomethacin on smooth muscle.

Authors:  B J Northover
Journal:  Br J Pharmacol       Date:  1971-03       Impact factor: 8.739

10.  Regional differences in the responsiveness of isolated arteries from cattle, dog and man.

Authors:  E Müller-Schweinitzer; H Weidmann
Journal:  Agents Actions       Date:  1977-09
View more
  3 in total

1.  Venoconstrictor responses to dihydroergocristine and dihydroergotamine: evidence for the involvement of 5-HT1 like receptors.

Authors:  E Müller-Schweinitzer
Journal:  Cardiovasc Drugs Ther       Date:  1990-12       Impact factor: 3.727

2.  Evidence for common pharmacological properties of [3H]5-hydroxytryptamine binding sites, presynaptic 5-hydroxytryptamine autoreceptors in CNS and inhibitory presynaptic 5-hydroxytryptamine receptors on sympathetic nerves.

Authors:  G Engel; M Göthert; E Müller-Schweinitzer; E Schlicker; L Sistonen; P A Stadler
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1983-09       Impact factor: 3.000

3.  2-[125Iodo]LSD, a new ligand for the characterisation and localisation of 5-HT2 receptors.

Authors:  G Engel; E Müller-Schweinitzer; J M Palacios
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1984-04       Impact factor: 3.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.